Gregory Michael Garvin, MD in Oxford, MI - Preventive Medicine

Gregory Michael Garvin, MD is a Preventive Medicine - Occupational Medicine physician based in Oxford, Michigan. Gregory Michael Garvin is licensed to practice in Michigan (license number 4301053628) and his current practice location is 760 Woodleigh Way, Oxford, Michigan. He can be reached at his office (for appointments etc.) via phone at (248) 838-8489.

NPI number for Gregory Michael Garvin is 1528185378 and his current mailing address is 760 Woodleigh Way, Oxford, Michigan. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1528185378.

Contact Information

	Gregory Michael Garvin, MD
	760 Woodleigh Way, Oxford, MI 48371
	(248) 838-8489
	(615) 778-9114

Physician's Profile

Full Name	Gregory Michael Garvin
Gender	Male
Speciality	Preventive Medicine - Occupational Medicine
Location	760 Woodleigh Way, Oxford, Michigan
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1528185378
Provider Enumeration Date: 03/26/2007
Last Update Date: 02/26/2014

Medical Identifiers

Medical identifiers for Gregory Michael Garvin such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1528185378	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2083X0100X	Preventive Medicine - Occupational Medicine	4301053628 (Michigan)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Gregory Michael Garvin is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Gregory Michael Garvin, MD 760 Woodleigh Way, Oxford, MI 48371 Ph: (248) 838-8489	Gregory Michael Garvin, MD 760 Woodleigh Way, Oxford, MI 48371 Ph: (248) 838-8489

News Archive

Raising either legal drinking age or beer taxes leads to fewer youth-traffic fatalities

A wide variety of public policies affect alcohol purchases, consumption, and traffic fatalities, The two alcohol-control policies that have been most-clearly demonstrated to reduce youth consumption and traffic deaths are raising the minimum legal drinking age (MLDA) and raising beer taxes.

Few easy ways to add more wellness to the day

Stir up sippable, flavorful drinks and snacking soups for easy ways to add more wellness to your day. Start with robust flavors like turmeric, cayenne and ginger then pair with wholesome ingredients like pineapple, dandelion greens and cucumber to create delicious sips to help you awaken, stay energized or replenish.

Clinician led management can fix the NHS

Clinician led management can fix the NHS, argues a senior doctor in this week's British Medical Journal. He calls on the government to let clinicians and managers plan and run their services free from political control.

Protein toxic to nerve cells in AD also contributes to memory loss

The underlying causes of Alzheimer's disease are not fully understood, but a good deal of evidence points to the accumulation of β-amyloid, a protein that's toxic to nerve cells. β-amyloid is formed by the activity of several enzymes, including one called BACE1. Most Alzheimer's disease patients have elevated levels of BACE1, which in turn leads to more brain-damaging β-amyloid protein.

Enterome, Bristol-Myers Squibb enter into Immuno-Oncology collaboration to identify new microbiome-derived biomarkers for cancer

Bristol-Myers Squibb (NYSE: BMY) and Enterome SA (Enterome), a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer.

Gregory Michael Garvin, MD - Preventive Medicine in Oxford, MI